![](/wp-content/uploads/2018/10/T42i2P76T76r2xbTvvoz.png)
$599
New Oramed Oral Insulin Ph2b Study Initiated
Oramed has initiated a Ph2b dose ranging study evaluating its oral insulin (ORMD-0801) in T2DM subjects (CT.gov record). According to the press release, the trial is a “prerequisite to Phase 3 confirmatory studies under FDA’s BLA.”